Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective is to compare effectiveness of ziprasidone treatment to current treatments (haloperidol, olanzapine or risperidone) measured by change in Brief Psychiatric Rating Scale (BPRS) scores versus baseline
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ziprasidone | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| The primary efficacy variable will be change from baseline in Brief Psychiatric Rating Scale (BPRS) total score |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline In Clinical Global Impression Severity (CGI-S) | ||
| Clinical Global Impression Improvement (CGI-I) | ||
| Change From Baseline In Positive and Negative Syndrome Scale (PANSS) Total |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Alexandria | Egypt | ||||
| Pfizer Investigational Site |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Change from baseline in scores on the Montgomery-Asberg Depression Rating Scale (MADRS) |
| Change from baseline in scores on the MADRS Without Items 4, 5 |
| Change from baseline in Global Assessment of Functioning (GAF) |
| Change From Baseline In Drug Attitude Inventory (DAI) |
| Change From Baseline In Weight |
| Change From Baseline In Prolactin And Lipid Levels |
| Change From Baseline in Modified Simpson Angus Scale (m-SAS) Total Score |
| Change From Baseline in Barnes Akathisia Scale (BAS) |
| Change From Baseline in Abnormal Involuntary Movement Scale (AIMS)- Movement Ratings Total Score |
| Change From Baseline in Abnormal Involuntary Movement Scale (AIMS)- Global Judgment Of Severity Total Score |
| Asyut |
| Egypt |
| Pfizer Investigational Site | Cairo | Egypt |
| Pfizer Investigational Site | Tanta | Egypt |
| Pfizer Investigational Site | Larissa | Mezourlo | 41110 | Greece |
| Pfizer Investigational Site | Athens | 11528 | Greece |
| Pfizer Investigational Site | Athens | 12462 | Greece |
| Pfizer Investigational Site | Athens | 15126 | Greece |
| Pfizer Investigational Site | Jordan | Jordan |
| Pfizer Investigational Site | Kuwait City | 13041 | Kuwait |
| Pfizer Investigational Site | Beirut | Lebanon |
| Pfizer Investigational Site | Khobar | 31451 | Saudi Arabia |
| Pfizer Investigational Site | Garankuwa | Gauteng | 0208 | South Africa |
| Pfizer Investigational Site | Krugersdorp | Gauteng | 1739 | South Africa |
| Pfizer Investigational Site | Noordheuwel, Krugersdorp | Gauteng | 1739 | South Africa |
| Pfizer Investigational Site | Bellair, Durban | KwaZulu-Natal | 4094 | South Africa |
| Pfizer Investigational Site | Pinetown, Durban | KwaZulu-Natal | 3600 | South Africa |
| Pfizer Investigational Site | Observatory, Cape Town | Western Cape | 7925 | South Africa |
| Pfizer Investigational Site | Ankara | Turkey (Türkiye) |
| Pfizer Investigational Site | Bursa | Turkey (Türkiye) |
| Pfizer Investigational Site | Erzurum | Turkey (Türkiye) |
| Pfizer Investigational Site | Istanbul | Turkey (Türkiye) |
| Pfizer Investigational Site | Izmir | 35340 | Turkey (Türkiye) |
| Pfizer Investigational Site | Izmir | Turkey (Türkiye) |
| Pfizer Investigational Site | Manisa | Turkey (Türkiye) |
| Pfizer Investigational Site | Şişli | Turkey (Türkiye) |
| Pfizer Investigational Site | Dubai | United Arab Emirates |
| ID | Term |
|---|---|
| D012559 | Schizophrenia |
| D011618 | Psychotic Disorders |
| ID | Term |
|---|---|
| D019967 | Schizophrenia Spectrum and Other Psychotic Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| C092292 | ziprasidone |
Not provided
Not provided
Not provided